Authors
Anezka Zemankova, Bohuslav Melichar, Michal Eid, Alexandr Poprach, Jindrich Kopecky, Tomas Buchler, Darja Sustrova, Sarka Stuhlova, Jan Dvorak, Zuzana Donatova, Pavel Vlcek, Katerina Zychackova, Jana Katolicka, Tomas Blazek, David Vrana, Ondrej Fiala, Petra Majkova, Adam Cepa, Hana Studentova
Published in
Future oncology (London, England). Pages 1-7. Sep 20, 2026. Epub Sep 20, 2026.
Abstract
Platinum-based chemotherapy (PBC) followed by avelumab first-line (1L) maintenance for patients with nonprogressive disease is a standard of care in locally advanced or metastatic urothelial carcinoma (la/mUC) in the Czech Republic. We report results from a retrospective analysis of a national reimbursement registry for avelumab maintenance. The objective was to assess the effectiveness and safety in routine clinical practice.
Registry data were collected between October 2021 and January 2024. Primary endpoint was overall survival (OS) from avelumab 1L maintenance; secondary endpoints included progression-free survival (PFS) and safety.
At data cutoff, 107 patients with la/mUC were treated with avelumab 1L maintenance, the median age was 72 years (range, 45-92), and the median follow-up was 8.2 months. Fifty-five patients (51.4%) received 1L cisplatin-based chemotherapy, 46 (43.0%) carboplatin-based chemotherapy, and six (5.6%) switched between regimens. Median OS was not reached, the 12- and 18-month OS rates were 79.3% and 68.0%. Limitations include low number of patients, retrospective design, and short follow-up.
These clinical outcomes are consistent with the JAVELIN Bladder 100 trial and other real-world studies, supporting the effectiveness and favorable safety profile of avelumab as 1L maintenance in patients with la/mUC that has not progressed with 1L PBC.
PMID:
42764721
Bibliographic data and abstract were imported from PubMed on 21 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 11
- Comments 0